Aspen Neuroscience Inc. has closed a series B financing of $147.5 million. The funds will help get its autologous neuron replacement candidate into a phase I/IIa study for Parkinson’s disease. Privately held Aspen has been talking about initiating the phase I/IIa clinical trial since at least 2019. But in April 2022, it came a lot closer to reality. That’s when the company launched its first patient screening studies at several sites in the U.S. Now, the trial-ready cohort study is designed to screen potential participants for the study.